Selected drugs that received regulatory approval in 2013. (A) Algeta ASA (OSE:ALGETA) is being acquired by Bayer AG (Xetra:BAYN); (B) Gentium S.p.A. (NASDAQ:GENT) is being acquired by Jazz Pharmaceuticals plc (NASDAQ:JAZZ); Source: BCIQ: BioCentury Online Intelligence

Company

Product

Indication

2013 approval

Actelion Ltd. (SIX:ATLN)

Valchlor mechlorethamine

Stage IA and IB mycosis fungoides, a type of cutaneous T cell lymphoma (CTCL)

U.S.

Actelion Ltd. (SIX:ATLN)

Opsumit macitentan

Pulmonary arterial hypertension (PAH)

Canada/EU/U.S.

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Juxtapid lomitapide (Lojuxta)

Homozygous familial hypercholesterolemia (hoFH)

EU (approved in U.S. 2012)

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)/Grupo Ferrer Internacional S.A.

Adasuve Staccato loxapine

Agitation in adults with schizophrenia or bipolar disorder

EU (approved in U.S. 2012)

Algeta ASA (OSE:ALGETA)/Bayer AG (Xetra:BAYN) (A)

Xofigo radium-223 dichloride

Castration-resistant prostate cancer (CRPC)

EU/U.S.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Iclusig ponatinib

Chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

EU (approved in U.S. 2012)

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR)

Nuedexta dextromethorphan/quinidine

Pseudobulbar affect (PBA)

EU (approved in U.S. 2010)

Basilea Pharmaceutica AG (SIX:BSLN)

Ceftobiprole

Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP)

EU

Bavarian Nordic A/S (CSE:BAVA)

Imvanex vaccine

Immunization against smallpox disease in adults

Canada/EU

Baxter International Inc. (NYSE:BAX)

Rixubis recombinant Factor IX (rFIX)

Hemophilia B

U.S.

Bayer AG (Xetra:BAYN)

Adempas riociguat

PAH and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH)

Canada/U.S.